ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3160

Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine

Candace H. Feldman1, Francisco M. Marty2, Wolfgang C. Winkelmayer3, Hongshu Guan4, Jessica M. Franklin5, Daniel H. Solomon1, Seoyoung C. Kim6 and Karen H. Costenbader7, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, 3Medicine-Nephrology, Baylor College of Medicine, Houston, TX, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: azathioprine, infection and mycophenolate mofetil, Lupus

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Patients with systemic
lupus erythematosus (SLE) are at high risk of
infections partly from use of immunosuppressives
(IS). Clinical trials are powered to detect differences in treatment efficacy
and therefore the comparative risks of infections are understudied. We compared
the rates of hospitalized infection and all-cause mortality among SLE patients
receiving mycophenolate mofetil
(MMF) vs. azathioprine (AZA), two
commonly and often interchangeably used IS. We hypothesized based on prior
small studies that MMF users may be at increased risk of infection and death.

Methods: We used Medicaid data
from 47 states and Washington, DC, 2000-2006, to identify adults (18-65 years)
with ≥2 SLE ICD-9 codes separated by ≥30 days, who were new
users of MMF or AZA with no use of either drug in the prior 183 days of
continuous Medicaid enrollment. The index date was the first MMF or AZA
prescription fill date. We excluded patients with HIV/AIDS or prior organ
transplant. We used multivariable logistic regression to calculate propensity
scores (PS) for receipt of MMF vs. AZA. Covariates included sociodemographics,
year, comorbidities, lupus nephritis, vaccines, healthcare utilization, hydroxychloroquine and other IS use during the 183 days
prior to the index date, and cumulative corticosteroid dose during the 60 days
prior to the index date. We matched new users of MMF and AZA by PS (1:1) and
conducted as-treated (AT) analyses, censoring at drug discontinuation, gaps
>30 days, switch to the comparator drug, death, disenrollment or end of
follow-up. In secondary intention-to-treat (ITT) analyses, patients were
censored at death, disenrollment or end of follow-up. We identified
hospitalized infections using a validated algorithm (PPV 80%) and used Cox
proportional hazard regression models to estimate hazard ratios (HR) of first
infection and death comparing PS-matched new users of MMF and AZA (referent).

Results: We identified 926
PS-matched pairs of MMF and AZA new users with SLE. Characteristics were well
balanced: mean age was 34 (SD 11) years, 92% were female, 45% were Black, 25%
White and 20% Hispanic. In AT analyses, the incidence rate (IR) of first
hospitalized infection per 100 person-years was 13.95 among MMF users and 11.91
among AZA users (Table). The hazard
ratio of first infection was similar for new MMF vs. AZA users (HR 1.18, 95% CI
0.80-1.75). Mortality rates per 100 person-years were 2.39 among MMF users and
1.74 among AZA users (HR 1.39, 95% CI 0.53-3.65). Findings of secondary ITT
analyses were similar to the AT analyses with no significant differences
between groups.

Conclusion: In this large, diverse
cohort of SLE patients, while the rates of hospitalized infection and all-cause
mortality were marginally higher among MMF vs. AZA new users, there were no
significant differences. Further studies are needed to determine whether there
are differences in other relevant safety outcomes.

Table. Propensity Score-Matched* Analyses of First Hospitalized Infection and All-Cause Mortality among SLE New Users of Mycophenolate mofetil (MMF) vs. Azathioprine (AZA)

Mycophenolate Mofetil (N=926)

Azathioprine (N=926)

Analysis**

Outcome

Events

Person-years

IR+ (95% CI)

HR++ (95% CI)

Events

Person-years

IR+ (95% CI)

HR++

As treated (AT)

First infection

56

401.5

13.95 (13.83-14.07)

1.18 (0.80-1.75)

46

386.3

11.91 (11.80-12.02)

Ref

Death

10

417.8

2.39 (2.35-2.44)

1.39 (0.53-3.65)

7

402.8

1.74 (1.70-1.78)

Ref

Intention-to-treat (ITT, 183 days)

First infection

79

401.7

19.67 (19.52-19.81)

1.13 (0.82-1.56)

70

402.1

17.41 (17.27-17.54)

Ref

Death

15

421.6

3.56 (3.50-3.62)

1.06 (0.51-2.2)

14

418.9

3.34 (3.29-3.40)

Ref

Intention-to-treat (ITT, 365 days)

First infection

116

690.8

16.79 (16.69-16.89)

1.25 (0.96-1.64)

93

694.8

13.39 (13.30-13.48)

Ref

Death

18

748.3

2.41 (2.37-2.44)

0.94 (0.49-1.79)

19

742.6

2.56 (2.52-2.60)

Ref

*Propensity scores included age, sex, race/ethnicity, US region, SLE comorbidity index (Ward MM, 2000), comorbidities, lupus nephritis, number of SLE and renal-related laboratory tests, number of  medications, immunosuppressive use, 60-day cumulative corticosteroid dose, NSAID use, healthcare utilization, vaccinations, and calendar year

**Mean follow-up for AT infection analysis was 0.43 (SD 0.53) person-years, for ITT (183 days) 0.43 (SD 0.13) person-years and for ITT (365 days) 0.75 (SD 0.33) person-years

+ IR is the incidence rate per 100 for first hospitalized infection and for all-cause death

++ HR is the hazard ratio calculated using Cox proportional hazard regression models of propensity score-matched MMF vs. AZA new users


Disclosure: C. H. Feldman, None; F. M. Marty, None; W. C. Winkelmayer, None; H. Guan, None; J. M. Franklin, None; D. H. Solomon, None; S. C. Kim, Pfizer Inc, 2,AstraZeneca, 2,Lilly, 2,Genentech and Biogen IDEC Inc., 2; K. H. Costenbader, None.

To cite this abstract in AMA style:

Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Kim SC, Costenbader KH. Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/comparative-rates-of-serious-infections-and-all-cause-mortality-among-systemic-lupus-erythematosus-patients-receiving-mycophenolate-mofetil-versus-azathioprine/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-rates-of-serious-infections-and-all-cause-mortality-among-systemic-lupus-erythematosus-patients-receiving-mycophenolate-mofetil-versus-azathioprine/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology